The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma

Molecular Cancer Research

Volumn 13, Issue 2, 2015, Pages 339-347

  Bianchi Frias, Daniella ^a   Hernandez, Susana A ^a   Coleman, Roger ^a   Wu, Hong ^b   Nelson, Peter S ^a  

^a USA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CHROMOSOME 11; CHROMOSOME 15; CHROMOSOME 19; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; STRUCTURAL CHROMOSOME ABERRATION; ADENOCARCINOMA; ANIMAL; CHROMOSOME; CHROMOSOME ABERRATION; EXPERIMENTAL NEOPLASM; GENETICS; PATHOLOGY; PROSTATE TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, MAMMALIAN; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS;

EID: 84923887222     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0262     Document Type: Article

References (50)

1. Irshad S, Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev 2012;32:109-22.
2. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the mouse models of human cancers consortium prostate pathology committee. Cancer Res 2013;73:2718-36.
3. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-5.
4. Greenberg NM, DeMayo F, Finegold MJ,MedinaD, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
5. Ahuja D, Saenz-RoblesMT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005;24: 7729-45.
6. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
7. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998;78:i-xv.
8. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
9. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
10. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol 2013;14:R125.
11. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 2012;72:1878-89.
12. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005;37:48-55.
13. Baca Sylvan C, Prandi D, LawrenceMichael S, Mosquera Juan M, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153:666-77.
14. Barbieri CE, Baca SC, Lawrence MS,Demichelis F, BlattnerM, Theurillat J-P, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-9.
15. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
16. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
17. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57: 3325-30.
18. Watson PA. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005;65:11565-71.
19. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007;67:6083-91.
20. Chiaverotti T, Couto SS, Donjacour A, Mao J-H,Nagase H, Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46.
21. Cutler G, Marshall LA, Chin N, Baribault H, Kassner PD. Significant gene content variation characterizes the genomes of inbred mouse strains. Genome Res 2007;17:1743-54.
22. Graubert TA, Cahan P, Edwin D, Selzer RR, Richmond TA, Eis PS, et al. A high-resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genet 2007;3:e3.
23. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R,Greenberg N, et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 2001;98:11563-8.
24. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004;11:1-18.
25. Seigne C, Fontaniere S, Carreira C, Lu J, Tong WM, Fontaniere B, et al. Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice. BMC Cancer 2010;10:395.
26. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, Cibulskis K, et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014;156: 1298-311.
27. Yi Y, Nandana S, Case T, Nelson C, Radmilovic T, Matusik RJ, et al. Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer.Mol Cytogenet 2009;2:18.
28. Gordon RR, Merrill ML, Hunter KW, Sùrensen P, Threadgill DW, Pomp D. Dietary fat-dependent transcriptional architecture and copy number alterations associated with modifiers of mammary cancer metastasis. Clin Exp Metastasis 2010;27:279-93.
29. Grim JE, Knoblaugh SE, Guthrie KA, Hagar A, Swanger J, Hespelt J, et al. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol 2012;32:2160-7.
30. Sweet-Cordero A, Tseng GC, You H, Douglass M, Huey B, Albertson D, et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 2006;45:338-48.
31. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, Rojas A, et al. TGF-β receptor inactivation and mutant kras induce intestinal neoplasms in mice via a β-catenin-independent pathway. Gastroenterology 2009;136:1680- 8.e7.
32. Bojovic B, Crowe DL. Dysfunctional telomeres promote genomic instability and metastasis in the absence of telomerase activity in oncogene induced mammary cancer. Mol Carcinog 2013;52:103-17.
33. Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, et al. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 1998;17:2403-11.
34. Standfuss C, Pospisil H, Klein A. SNP microarray analyses reveal copy number alterations and progressive genome reorganization during tumor development in SVT/t drivenmice breast cancer.BMCCancer 2012;12:380.
35. Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, et al. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 2006;66:3452-5.
36. Podsypanina K, Li Y, Varmus HE. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med 2004;2:24.
37. Bennett CN, Green JE. Unlocking the power of cross-species genomic analyses: identi fication of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res 2008; 10:213.
38. Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes Dev 2011;25:534-55.
39. Ding Z, Wu C-J, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012;148:896-907.
40. Hodgson JG. Copy number aberrations inmouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. Cancer Res 2005;65:9695-704.
41. Kim M, Gans JD, Nogueira C, Wang A, Paik J-H, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81.
42. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
43. Montagna C, Andrechek ER, Padilla-Nash H, Muller WJ, Ried T. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 2002;21:890-8.
44. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002;21:5097-107.
45. Weaver ZA, McCormack SJ, LiyanageM, du Manoir S, Coleman A, Schrock E, et al. A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer 1999;25:251-60.
46. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
47. Maser RS. Connecting chromosomes, crisis, and cancer. Science 2002;297:565-9.
48. Maser RS, Wong KK, Sahin E, Xia H, Naylor M, Hedberg HM, et al. DNAdependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Mol Cell Biol 2007;27:2253-65.
49. Padilla-Nash HM, McNeil NE, Yi M, Nguyen QT, Hu Y, Wangsa D, et al. Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells. Carcinogenesis 2013;34:1929-39.
50. Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, et al. Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics 2013;8:1254-60.